

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or analyte thereof related to said disease state; and

*a<sup>2</sup>  
Cont* means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

---

29. Polyclonal antibodies produced against a marker sequence ID selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or at least one analyte thereof in at least one animal host.

*a<sup>3</sup>*  
30. An antibody that specifically binds a biopolymer including a marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or at least one analyte thereof.

---

33. A process for identifying therapeutic avenues related to a disease state comprising:  
conducting an analysis as provided by the kit of claim 18; and  
interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or at least one analyte thereof;  
whereby therapeutic avenues are developed.

*a<sup>4</sup>*  
*cont*

34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or at least one analyte thereof.

*a<sup>5</sup>*

38. A process for regulating a disease state by controlling the presence or absence of a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or at least one analyte thereof.

REMARKS

The foregoing Supplemental Preliminary Amendment is made so as to further bring this application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added. Examination on the merits is respectfully requested.